N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Establishment of a Biological Collection to Develop Translational Preclinical Models for the Study of Tumors and Diseases of the Gastrointestinal Tract

Sponsor: University Hospital, Strasbourg, France • ClinicalTrials.gov ID: NCT07782203

Registry updated: 2026-08-24
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The causes underlying the development of chronic inflammatory bowel diseases (IBD) and digestive cancers remain poorly understood. They involve both genetic susceptibilities and multiple environmental factors. Research and the development of new therapeutic strategies are essential to provide patients with novel treatment opportunities. A deep understanding of the tumor ecosystem at the molecular level, as well as the interactions between different cell types, is crucial to identify and validate new therapeutic targets. Since animal cancer models have shown their limitations in translating results to humans, studies models are often based on autologous patient tissues and sera. These innovative models make it possible to: * model tumors ex vivo, * perform screenings of new candidate molecules, * or test tumor response to existing therapies in the context of personalized medicine. This work has led to numerous publications on advanced digestive cancers, such as those of the liver or the bile acid pathway To create ex vivo models and reconstruct the tumor in vitro, experiments require treating tumor cells with blood from the same patient (autologous), collected simultaneously with the tumor resection. The tumor tissues used in culture are obtained from residual material of anatomopathological analyses performed as part of clinical care.

Interventions

  • biopsy (Procedure)
    collect tissues and blood cell

Eligibility criteria

Inclusion Criteria: * Diagnosed with IBD and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with digestive tract cancer on IBD and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with digestive cancer (esophagus, stomach, colon/rectum) and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with Barrett's esophagus and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care Exclusion Criteria: * All other

Conditions

Gastrointestinal Cancer IBD

Locations

  • Hôpitaux Universitaires de Strasbourg — Strasbourg, France
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record